• 약학회지
• /
• 제56권2호
• /
• pp.116-125
• /
• 2012

Local pharmaceutical companies in Korea, which have grown focusing on domestic markets, have recently faced difficulties such as market saturation, price control policies and market-opening pressures by FTA. It seems to be an urgent issue for them to export pharmaceuticals to developed countries comprising the greater part of the global pharmaceutical market. Hence, this research was conducted to investigate and benchmark the strategies employed by India industry for the successful access to the global pharmaceutical markets. Drug policies as well as their influences on pharmaceutical market changes between India and Korea for the last 40 years have been searched and the differences have been comparatively analyzed. The pharmaceutical industry of India has the following strengths: low costs; experienced labor pool; excellent reverse-engineering skills; powerful IT; marketing capability; and established distribution network. After 2000, consolidations, M&A and alliances with domestic and multinational companies have been sharply increased in the industry of India. Indian companies unfolding both competition and cooperation with multinational corporations currently move up the value-added chain, and this enthusiastic strategy should be learned by local pharmaceutical companies.

• 무역학회지
• /
• 제47권5호
• /
• pp.95-113
• /
• 2022

Tariffs on pharmaceuticals are generally low, but the time-consuming and costly licensing procedures of importing countries may act as barriers to trade. Accordingly, in terms of improving export competitiveness through cost reduction of exporting countries and improving public health for importing countries, international regulatory collaboration is effective for both countries. However, little is known about the impact of cross-border cooperation in pharmaceutical regulation on international trade. This study empirically analyzed the effect of cross-border regulatory collaboration on pharmaceutical trade using the gravity model. It was confirmed that the regulatory collaboration measures had a trade promotion effect in all drugs(HS29+HS30), finished drugs (HS30), and vaccines (HS300220). This study is meaningful in that it empirically analyzed with the consideration of the reference pharmacopoeia, safety and effectiveness in addition to the GMP inspection used in the previous study.

• 무역상무연구
• /
• 제78권
• /
• pp.119-143
• /
• 2018

This research aims to review every important academic research on risk management in FTA and to suggest a future area for further research. This research area seems to focus on conceptual study or fact finding rather than on theory development or empirical research on causal relationship or theory testing. The National Assembly Digital Library analyzed the results of 3,576 researches on thesis and journals fromthe results of the FTA. Research on FTA is analyzed in four major themes. First, there have been previous studies on business performance such as FTA export performance and economic effect. Second, analyzed the effects of FTA in product and service. The products are classified into agricultural, marine products, manufacturing, textiles and clothing, medicinal pharmaceuticals, cosmetics, and others. Services are classified into educational and cultural contents, service industry and financial industry. Third, research on the risk management of FTA Origin is broadly classified into the use of country of origin and the verification of origin, and the use of origin includes the study of rules of origin and systems of origin and management. Origin verification was divided into origin verification and origin risk management. Fourth, study on the conclusion area of the FTA, studies were conducted on areas such as Korea-US FTA, Korea-China FTA, Korea-EU FTA, Korea-Japan FTA, Korea-Chile FTA, and Korea-ASEAN FTA. Search results through the FTA, focused on analyzing the FTA area and concept research by research purpose. In addition, research methods are mainly focused on documentary survey, and research areas are concentrated on specific countries such as China and USA. This implies a necessity for a future development in that research area. Other areas for future research may include case research on actual failures in FTA, proactive risk management strategy, and integrated risk management for export companies. Risk management in FTA may help investment expansion, and that is why research on the issue matters.

• 무역학회지
• /
• 제45권2호
• /
• pp.51-65
• /
• 2020

According to an analysis of 560 foreign-invested companies investing in South Korea's manufacturing industry, the following three facts were found. First, the proportion of sales by manufacturing foreign-invested companies is divided into 68.5 percent of domestic sales and 31.5 percent of exports. From 68.5 percent of domestic sales, sales to Korean companies are 60.5 percent, including 37.1 percent for large companies and 23.4 percent for small and medium-sized companies, while only 8.0 percent for domestic consumers. Second, the investment sectors of manufacturing foreign-invested enterprises are 'machine and equipment manufacturing', 'chemical and chemical-chemical material manufacturing-excluding pharmaceuticals', 'electronic components, computers, video, sound and communication equipment manufacturing' and 'vehicle and trailer manufacturing'. It overlaps with electric·electronics, petro-chemicals and automobiles, which are Korea's main industries and areas of Korean global companies. Third, 31.5 percent of the sales of foreign-invested companies in the manufacturing sector are exported. Foreign-invested companies export their products to use them for their parents or affiliates or to the third countries. The analysis shows that foreign-invested companies invested in Korea for B2B transactions with Korean companies. The implications are that Korea can attract foreign investments by utilizing Korean companies' demand for intermediate goods. Foreign-invested companies can invest in Korea in order to use Korea, which has signed free trade agreements with the US, the EU and ASEAN, as an export platform.

• 한국버섯학회지
• /
• 제14권4호
• /
• pp.142-154
• /
• 2016

세계의 버섯 생산량은 매년 10-20% 증가해 왔으며 다품목화 되어가고 있다. 최근에는 큰느타리, 백령느타리 등이 새로운 품목으로 재배 면적이 증가하고 있다. 특히 중국은 2002년 870만 톤으로 세계생산량 71.5%를 차지하였다. 한국도 유사한 경향을 나타내고 있다. 우리나라에서는 고려시대 저술한 김부식의 삼국사기(1145년)에 처음으로 금지(영지)와 서지가 기록되었고, 조선시대에는 17종류 이상의 농서 또는 의학서에서 버섯의 이용이 기록되었다. 상업적으로 이용되는 버섯으로는 지금까지 38종의 200품종 이상이 육성 보급되었다. 원형질체 융합에 의한 '원형느타리'가 1989년에 개발 보급되었는데 이는 느타리 품질 기준을 바꾸었다. 버섯 생산은 2015년에 199,829 톤으로 생산가액 약 8,500억 원을 능가할 것으로 추정된다. 주요 생산버섯은 느타리, 큰느타리, 팽이, 표고, 양송이, 영지로 전체의 90% 이상을 차지한다. 버섯 수출이 1960년 시작된 이후 수출과 수입은 증가되어 왔다. 병재배시스템 개발과 액체종균 사용으로 생산비가 절감되어 수출증가를 이끌었다. 하지만 일부 버섯의 높은 생산비로 수입도 증가하였다. 농촌진흥청에서 1977년부터 버섯의 유전체 연구를 시작하였다. 팽이버섯의 게놈 염기서열 분석은 분자육종에 이바지할 것이다. 또한 약용버섯인 동충하초 게놈 연구도 기능성 산물 개발에 기여할 것이다. 버섯은 다양한 생리활성이 보고되었다. 버섯산물인 의약품, 강장제, 건강음료, 기능성 생물전환제, 가공품 등이 개발되어 시중에서 유통되고 있다. 버섯의 수확 후 배지의 사료화 및 퇴비제조도 이루어지고 있다.

• 한국버섯학회지
• /
• 제3권1호
• /
• pp.1-23
• /
• 2005

세계의 버섯 생산량은 매년 10-20% 증가해 왔으며 다품목화 되어가고 있다. 최근에는 큰느타리, 백령느타리 등이 새로운 품목으로 재배 면적이 증가하고 있다. 우리나라에서는 고려시대 저술한 김부식의 삼국사기(1145년)에 처음으로 금지(영지)와 서지가 기록되었고, 조선시대에는 16종류 이상의 농서 또는 의학서에서 버섯의 이용이 기록되었다. 상업적으로 이용되는 버섯으로는 지금까지 25종의 160품종이 보급되었다. 하지만 품종보호등록은 8품종만이 이루어져 아주 적은 편이다. 버섯산업이 1960년대 수출산업으로 육성되면서 자실체 생산량은 계속 증가해왔다. 2003년에는 181,828톤으로 생산가액 약 8,000억원을 능가할 것으로 추정된다. 버섯의 유효성분이 많이 알려지고 있는데 항균, 항염증, 항종양, 항바이러스, 항세균과 항기생물, 혈압조절, 심장혈관 장애 방지, 콜레스테롤 과소혈증과 지방과다 혈증 방지, 항당뇨, 면역조절, 강신장, 간장 독성 보호, 신경섬유 활성화, 생식력 증진의 효과가 있다. 따라서 버섯 의약품, 건강음료, 가공식품, Biotransformation에 의한 신기능성 제품 개발 등이 이루어지고 있다. 또한 버섯은 환경정화 기능이 뛰어나 환경오염 물질의 정화가 가능하며, 버섯재배후 배지를 이용하여 퇴비생산, 가축사료 생산에 이용된다. 한국의 버섯산업은 이미 가장 빨리 성장하는 농업 투자분야로 되었다. 그러나 버섯산업의 국제 경쟁력 강화를 위하여 국내고유의 품종개발에 의한 품종보호등록이 시급하다. 또한 저렴한 생산기술 개발과 유통구조 개선에 의한 생산량 조절이 이루어져야 버섯산업이 더욱 발전할 수 있을 것이다.